New Jersey's 7th congressional district representative, Thomas Kean Jr, has recently made a series of transactions in his investment portfolio, according to a recent congressional trade report. The transactions, which took place in December 2024 and were reported in January 2025, involve a range of companies listed on various stock exchanges.
Kean Jr purchased stocks in Abbott Laboratories (NYSE:ABT), Analog Devices , Inc. (NASDAQ:ADI), Canadian Pacific Kansas City Limited (NYSE:CP), PERNOD RICARD S A SP/ADR (OTCMKTS:PRNDY), and Prologis , Inc. (NYSE:PLD). The value of each purchase fell within the $1,001 - $15,000 range.
In the same period, Kean Jr also sold stocks of Alphabet (NASDAQ:GOOGL) Inc. - Class C Capital Stock (NASDAQ:GOOG) and a partial sale of Franklin Resources, Inc. Common Stock (NYSE:BEN). Both sales were valued between $1,001 - $15,000. According to InvestingPro data, GOOG has shown impressive performance with a 33% return over the past year and is currently trading near its 52-week high of $203.84. InvestingPro analysis indicates the stock is currently fairly valued.
All transactions were made under the Kean Family Partnership, in which Kean Jr holds a 33% interest. This investment vehicle is based in the US.
These transactions reflect the ongoing active management of Kean Jr's investment portfolio. The congressional trade report did not indicate whether the transactions resulted in any capital gains over $200. InvestingPro highlights Alphabet's strong financial health with an excellent balance sheet, maintaining more cash than debt. Subscribers can access 10+ additional ProTips and comprehensive financial metrics through the Pro Research Report.
As a reminder to our readers, the STOCK Act requires members of Congress to disclose their transactions to ensure transparency and avoid conflicts of interest. This report confirms that Thomas Kean Jr has complied with these requirements for the reported period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.